Hironic Co.Ltd
KKRX:1499803,915.00
KRW
-15.00
(-0.38%)
ISIN
KR7149980005
Return %
Stock
S&P 500
1Y
-23.08
14.39
3Y
-48.99
81.42
5Y
-18.49
68.62
Capital Structure
KRW
•
in mil. unless spec.Working Capital
KRW
•
in mil. unless spec.Growth Rates
KRW
•
in mil. unless spec.Quarterly Revenue
KRW
•
in mil. unless spec.Quarterly Earnings Per Share
KRW
•
in mil. unless spec.Quarterly Dividends Per Share
KRW
•
in mil. unless spec.Company Description
- Full Time Employees
- 91
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- Yongin-si South Korea
- IPO Date
- Dec 17, 2014
- Website
- hironic.com
- Similar Companies
- Business
- Hironic Co., Ltd. is a South Korea-based medical device company engaged in the research, development, manufacturing, and global commercialization of energy-based aesthetic and dermatological treatment equipment and consumer beauty devices. Founded in 2006 and headquartered in Yongin-si, Gyeonggi-do, South Korea, the company operates across two primary business segments: Professional Medical Aesthetic Devices and Home Beauty Devices. The company's core product portfolio encompasses: High-Intensity Focused Ultrasound (HIFU) and Micro-Focused Ultrasound (MFU) systems, notably the DOUBLO series (including DOUBLO, DOUBLO-S, DOUBLO-GOLD, and New Doublo 2.0) and V-RO systems, designed for non-invasive skin tightening, tissue lifting, and facial contouring; Radiofrequency (RF) and multi-modality platforms, such as GENTLO and SILKRO, utilizing fractional microneedle RF and plasma technologies for skin rejuvenation, scar revision, and tissue coagulation; Laser and optical therapy equipment, headlined by the PICOHI picosecond Nd:YAG laser system for tattoo removal, hyperpigmentation treatment, and skin resurfacing; Needle-free kinetic transdermal delivery systems, comprising the SYNERJET and SYNERJET PRO platforms, which utilize pneumatic jet acceleration to administer liquid solutions subdermally without hypodermic needles; Non-invasive body contouring systems, including MICOOL and MIGLOU cryolipolysis devices for localized subcutaneous fat reduction; and Consumer at-home skincare devices, marketed through its specialized subsidiary Attibe Beauty Co., Ltd., which develops personal lifting and anti-aging devices such as HomeThera and Innolif. Hironic distributes its systems and proprietary single-use consumables to dermatology clinics, plastic surgery practices, medical spas, and hospital networks domestically in South Korea and across more than 60 international markets throughout Asia-Pacific, Europe, the Middle East, and the Americas. In recent corporate developments, Hironic has expanded its regulatory and commercial footprint across key global markets. The company obtained 510(k) clearance from the United States Food and Drug Administration (FDA) as well as medical device approval from South Korea's Ministry of Food and Drug Safety (MFDS) for its advanced SYNERJET PRO kinetic drug delivery system. In addition, the company secured domestic MFDS approval and commenced the commercial rollout of MIGLOU, its next-generation body contouring platform. Operationally, following the mutual termination of a proposed majority share sale agreement with Dongwha Pharm, Hironic reaffirmed its independent growth strategy, concentrating capital resources on direct international market penetration, expanding its proprietary consumable cartridge sales, and accelerating R&D across combined ultrasound-radiofrequency aesthetic technologies.